Related Experiment Video
Updated: May 30, 2026
04:41
Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
Published on: January 9, 2020
Alzheimer's disease genetics: lessons to improve disease modelling
1Department of Molecular Neuroscience, University College London Institute of Neurology, Queen Square, London WC1N 3BG, UK.
Biochemical Society Transactions
|July 27, 2011
Summary
Genome-wide association studies (GWAS) have advanced Alzheimer's disease (AD) research. Integrating GWAS findings with biological pathways is crucial for developing effective animal models to understand AD.
Area of Science:
- Genetics and Genomics
- Neuroscience
- Disease Modeling
Background:
- Alzheimer's disease (AD) poses a significant public health challenge.
- Genome-wide association studies (GWAS) have identified numerous genetic loci associated with AD risk.
- Understanding the biological underpinnings of AD genetics is critical for therapeutic development.
Purpose of the Study:
- To review the historical progression and key findings of GWAS in Alzheimer's disease research.
- To integrate current GWAS results with established biological processes and pathways relevant to AD.
- To highlight the importance of these integrated findings for the development of accurate AD animal models.
Main Methods:
- Comprehensive literature review of GWAS studies in Alzheimer's disease.
- Synthesis of genetic findings with known biological pathways and mechanisms.
- Analysis of the implications of GWAS for animal model development.
Main Results:
- Summary of significant genetic variants and loci identified through GWAS for AD.
- Integration of identified genetic factors with cellular and molecular pathways implicated in AD pathogenesis.
- Discussion of how GWAS data can inform the design and validation of AD animal models.
Conclusions:
- GWAS has been instrumental in uncovering the genetic architecture of Alzheimer's disease.
- Connecting genetic discoveries with biological pathways is essential for a deeper understanding of AD.
- The development of robust animal models, guided by integrated genetic and pathway knowledge, is paramount for future AD research and therapeutic strategies.
More Related Videos
09:33Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
09:45Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:28Human Genetics
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...